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ABSTRACT: Background: Ventral hernias are prevalent results 
in abdominal surgeries and may represent a surgical challenge 
in complex cases, mainly due to tension in abdominal wall 
musculature. Failure of surgical correction may lead to a more 
morbid treatment, in addition to a considerable socioeconomic 
impact. In order to have a lower risk of complications, the use of 
botulinum toxin A (BTA), may be a preoperative alternative to 
reduce abdominal wall tension by causing sustained and reversible 
paralysis. This critical review of the literature proposes to evaluate 
the adjacent use of BTA in surgical ventral hernias corrections. 
Methods: Using the PubMed database, the keywords ‘ventral 
hernia’, and ‘botulinum toxin’ were searched using the Boolean 
operator AND. Articles were selected based on their relevance 
and updated information. The outcomes of interest included the 
change in ventral hernia defect width and in lateral abdominal 
wall muscle length, pain, hernia recurrence and complications. 
Results: A total of 20 articles from 2009 to 2018 were found. We 
excluded some articles due to irrelevant technique, use of animal 
models and lack of outcome data. Reduction of the abdominal 
wall thickness increasing its length, less perioperative pain, hernia 
reduction and the correction with less tension were observed 
after the use of BTA injection. No complications occurred during 
applications. Conclusion: The use of BTA seems to be a promising 
alternative in the management of ventral hernias due to its capacity 
of reducing tension in the abdominal wall. However, more studies 
are necessary to determine the efficacy of this method.
Keywords: Botulinum toxin, type A; Herniorrhaphy; Abdominal 
wall/surgery; Ventral hernia; Incisional hernia. 
RESUMO: Introdução: Hérnias ventrais são um resultado 
prevalente de cirurgias abdominais que podem representar um 
desafio cirúrgico em casos complexos, principalmente devido à 
tensão na musculatura da parede abdominal. A falha na correção 
cirúrgica pode levar a necessidade de um tratamento mais 
mórbido, além de um considerável impacto socioeconômico. Para 
que o risco de complicações seja menor, o uso da toxina botulínica 
A (TBA) pode ser uma alternativa pré-operatória para reduzir a 
tensão da parede abdominal, através de uma paralisia sustentada 
e reversível. Esta revisão crítica da literatura propõe avaliar o uso 
adjacente de TBA em correções de hérnias ventrais cirúrgicas. 
Métodos: Usando o banco de dados PubMed, as palavras-chave 
“ventral hernia” e “botullinum toxin” foram pesquisadas usando o 
operador “AND”. Os artigos foram selecionados com base em sua 
relevância e informações atualizadas. Os desfechos de interesse 
incluíram a mudança na largura do defeito da hérnia ventral e 
no comprimento do músculo da parede abdominal lateral, dor, 
recidiva de hérnia e complicações. Resultados: Foram encontrados 
20 artigos de 2009 a 2018. Foram excluídos artigos devido à 
técnica irrelevante, uso de modelos animais e falta de dados 
sobre resultados. Redução da espessura da parede abdominal 
aumentando seu comprimento, menos dor perioperatória, redução 
de hérnia e correção com menos tensão foram observados após o 
uso da injeção de BTA. Nenhuma complicação ocorreu durante as 
aplicações. Conclusão: O uso de TBA parece ser uma alternativa 
promissora no manejo de hérnias ventrais devido à sua capacidade 
de reduzir a tensão na parede abdominal. No entanto, mais estudos 
são necessários para determinar a eficácia deste método.
Descritores: Toxinas botulínicas tipo A; Herniorrafia: Parede 
abdominal/cirurgia; Hernia ventral; Hernia incisional.
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INTRODUCTION
In abdominal surgery 28% of patients can develop ventral hernia1. In order to correct this 
hernia defects there are some techniques described such 
as anterior component separation (ACS), the posterior 
component separation (PCS), progressive preoperative 
pneumoperitoneum (PPP), mesh reinforcement, and 
optimal suturing techniques for large incisional hernias.
In this type of procedures, is frequent high 
recurrence rates, ranging from 12%–54%2. Failure in the 
correction of hernia defect generates higher costs to the 
health care system, greater morbidity to the patient and 
more complexity in reconstructive surgical technique.  
The success of surgical approach of the hernia 
depends on a variety of factors, such as the technique 
employed, the patient’s comorbidities, and the size of 
the hernia defect. The European Hernia Society (EHS) 
establishes large incisional hernias (W3) according with the 
diameter of 10 cm or larger3. In these conditions, it`s more 
difficult to repair without tension, which is fundamental for 
myofascial closure of the abdominal wall, what increases 
the risk of recurrence. 
In this context, there are some techniques used to 
approach a first incisional hernia repair relieving tension. 
The ACS technique described by Ramirez et al.4 permits 
fascial repositioning through lateral stretching, restoring 
the integrity of the abdominal wall. However, we find in 
the literature significant rates of recurrence associated with 
this procedure. Another technique used is the PCS, which 
increases the size and assures fascial closure; and it was 
most recently described in the treatment of large ventral 
hernia defects5,6,7.
In more complex cases, these techniques alone are 
not sufficient to guarantee the closure of the hernia defect, 
with the appropriate tension. To achieve a lower risk of 
complications other techniques can be used, such as PPP 
and the placement of expanding tissues on the abdominal 
wall6. Following the same principle, a recent proposal is 
the preoperative application of botulinum toxin A (BTA), 
a neurotoxic protein produced by Clostridium botulinum, 
for hernia correction, in order to relax and stretch the 
musculature. 
BTA has been used in medical practice for 
treatment of a great variety of conditions. It`s preoperative 
application, can induce a sustained and reversible flaccid 
muscular paralysis helping the closure of the abdominal 
wall, which should help to lower the recurrence rate1,2,8.
Abdominal wall reconstruction may benefit of 
the use of Botox injections to help in the abdominal 
components separation. The objective of this study was to 
conduct a critical review of the literature on the use of BTA 
in the surgical correction of Ventral Hernia.
METHODS
Eligibility criteria
The study population was patients undergoing 
ventral hernia repair. The intervention was administration 
of BTA as an adjunct to surgical hernia repair. The primary 
quantitative outcomes of interest included the decrease 
in ventral hernia defect width and the increase in lateral 
abdominal wall muscle length following BTA injection. 
Secondary outcomes of interest included pain, hernia 
recurrence, complications, length of stay, and length of 
follow-up.
Literature search
This critical review of the literature was performed 
using the PubMed database to search for published articles 
to include studies evaluating the effects of Botox on ventral 
hernias. The keywords ‘ventral hernia’ and ‘botulinum 
toxin’ were searched using the Boolean operator AND.
RESULTS
A total of 20 articles from 2009 to 2018 were found. 
These articles were selected based on their relevance and 
updated information.
Figure 1 – Flow-diagram of studies included in the 
review
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Table 1. Included studies and characteristics
Authors Year Design
Number  
of 
patients
Primary outcome Secondary outcome BTA dosage
Zendejas 
B, et al. 2013 Retrospective n = 22
Patients used less analgesia 
and reported less pain and, 
there was no difference in 
postoperative complications 
300 Units
Ibarra-
Hurtado 
TR, et al.
2014 Prospective n=17
It was observed reduction in muscle 
thickness and increase in muscle 
length on both sides. Left muscle 
thickness presented a mean reduction 
of 1±0.55cm (p<0.001). Right muscle 
thickness presented a mean reduction 
of 1.00±0.49cm (p<0.001). Left muscle 
length presented a mean increase of 
2.44±1.22cm (p<0.001). Right muscle 
length presented a mean increase of 
2.59±1.38cm (p<0.001).
No recurrences at mean 
follow-up of 49 months were 
observed
500 units 
(250 each 
side)
Farooque 
F, et al. 2016 Prospective n=8
Increase in mean length of lateral 
abdominal wall from 18.5 cm pre-BTA 
to 21.3 cm post-BTA (P = 0.017) with a 
mean unstretched length gain of 2.8 cm 
per side (range 0.8-6.0 cm). 
All hernias were surgically 
corrected with mesh with no 
early recurrence.
300 Units
Elstner KE, 
et al. 2016 Prospective n=27
Increase in mean length of the lateral 
abdominal wall from 15.7cm pre-BTA 
to 19.9 cm post-BTA (p<0.0001), with 
mean unstretched length gain of 4.2cm/
side (range 0-11.7cm/side)
No early recurrences.
Most patients 
received a 
total dose of 
300 units 
Ibarra-
Hurtado 
TR, et al.
2009 Prospective n=12 Pre BTA mean defect width of 13.9 cm; mean reduction was 5.25cm (p<0.001).
No recurrences at a mean 
follow-up of 9.08 months.
500 units 
(250 each 
side)
Zielinski 
MD, et al. 2013 Retrospective n=18
In this study, the rates of primary and 
partial fascial closure were 83% and 
6%, planned ventral hernia was 11%, 
complications was 67%, and mortality 
was 11%.
Reported rates of 
complications (67%), and 
mortality (11%).
300 units
Bueno-
Lledó J, 
et al.
2017 Retrospective n=45
 Was obtained an average value of 
reduction of 14% of the volumes of 
the incisional hernia (VIH)/abdominal 
cavity (VAC) ratio after (PPP) and BTA 
(p<0.05).
No complications 
occurred during the BT 
administration.
500 units 
Elstner KE, 
et al. 2017 Prospective n=32
Increase in mean baseline abdominal 
wall length from 16.4 to 20.4cm per side 
(p<0.0001) and the increase in mean 
transverse length of the unstretched 
anterolateral abdominal wall muscles of 
4.0cm/side (range 0-11.7cm/side).
No hernia recurrences. 300 Units
Rodriguez-
Acevedo 
O, et al.
2017 Prospective n=56
In this study was obtained an increase in 
mean lateral abdominal wall length from 
16.1 cm to 20.1cm per side, a mean gain 
of 4.0cm/side (range 1.0-11.7cm/side) 
(p<0.0001), and the unstretched mean 
length increase was 8.0 cm of the lateral 
abdominal wall. 
One patient presented with a 
new fascial defect 26 months 
post-operative.
300 or 
200 units 
depending on 
the patient
Bueno-
Lledó J, 
et al.
2018 Retrospective n=70
Mean reduction of 16.6% of the volumes 
of the incisional hernia (VIH)/abdominal 
cavity (VAC) ratio after (PPP) and BTA 
was obtained (p < 0.05).
No complications 
occurred during the BT 
administration.
500 Units
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DISCUSSION
The incisional hernia is often common delayed 
complication following laparotomies surgeries. Some 
comorbidities such as diabetes, obesity, male sex, advanced 
age, incision type, immunosuppression therapy, wound 
infection and pulmonary complications are considered risk 
factors for incisional hernia development9,10. Closure of the 
abdominal wall with low tension with the use of mesh is 
the standard treatment for correcting this type of hernia5. 
Tension in the sutured area is commonly associated with 
ischemia in the abdominal wall, that can result in great 
probability of recurrence of the hernia defect. In large 
hernia cases, complementary techniques to stretch the 
abdominal wall are necessary in order to guarantee success 
of the surgical approach.
BTA is a therapeutic complementary treatment 
to decrease the suture tension and consequently the 
hernia recurrences rate. The flaccid muscular paralysis, 
provoked by this neurotoxin, takes effect from two days 
after application and lasts for 6–9 months10. It reduces 
the thickness of the abdominal wall, increasing its length, 
allowing hernia reduction and therefore allowing closure 
with less tension.
In a 2014 clinical trial of male trauma patients 
with hernia secondary to open abdomen management, 
Ibarra-Hurtado TR et al showed that left muscle thickness 
mean reduction was 1 ± 0.55 cm (p < 0.001), right muscle 
thickness mean reduction was 1.00 ± 0.49 cm (p < 0.001), 
left muscle length mean increase was 2.44 ± 1.22 cm (p < 
0.001), and right muscle length mean increase was 2.59 ± 
1.38 cm (p < 0.001)1,11. 
With a similar approach, Farooque et al.12 in a 
prospective pilot study in 2016, showed that post-BTA 
preoperative computed tomography showed a significant 
increase in mean length of lateral abdominal wall: 18.5 cm 
pre-BTA to 21.3 cm post-BTA (P = 0.017) with a mean 
unstretched length gain of 2.8 cm per side (range 0.8-
6.0 cm)12. 
A 2016 prospective evaluation of 27 patients 
undergoing elective complex ventral hernia laparoscopic 
repair, conducted by Elstner et al.13, found similar positive 
results demonstrating an increase in mean length of the 
lateral abdominal wall from 15.7 cm pre-BTA to 19.9 cm 
post-BTA (p < 0.0001), with mean unstretched length gain 
of 4.2 cm/side (range 0-11.7 cm/side)13.
The injections of BTA minimizes the forces of 
traction on the area of closure during postoperative 
recuperation and the period of scarring of the operative 
wound. This promotes adequate perfusion to the area of 
the scarring, reducing postoperative morbidity, including 
pain, increasing the chances of successful primary closure 
of the incisional hernia14.
A systematic review and meta-analysis of botulinum 
toxin for management of ventral hernia done by Weissler 
et al.8 in 2017, showed significant hernia width reduction 
(mean = 5.79 cm; n = 29; p < 0.001) and lateral abdominal 
wall muscular lengthening (mean = 3.33 cm; n = 44; 
p < 0.001) following BTA applications8.
The advantage of the combination of abdominal 
wall reconstruction with the use of BTA is the minimal 
tension and protection of the sutures in the postoperative 
phase, what reduces the risk of recurrence, pain, and 
complications1,5,8,10-13,15-17.
CONCLUSION
A number of aspects of the closure of ventral 
incisional hernias remain controversial; among these is the 
use of botulinum toxin A. This paper describes a critical 
review, involving the application of BTA in the correction 
of ventral hernia defects. BTA seems to reduce the tension 
of the sutures in the postoperative phase, improving the 
patient’s outcomes. But given the complexity of such 
cases, however, more studies are necessary to determine 
the efficacy of this method.
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